NYSE:MYOV - Myovant Sciences Stock Price, Forecast & News

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Myovant Sciences Ltd (NYSE:MYOV) posted its earnings results on Tuesday, November, 12th. The company reported ($0.79) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.73) by $0.07. View Myovant Sciences' Earnings History.

Myovant Sciences is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Myovant Sciences.

8 analysts have issued 1-year price objectives for Myovant Sciences' stock. Their forecasts range from $20.00 to $34.00. On average, they expect Myovant Sciences' stock price to reach $26.00 in the next twelve months. This suggests a possible upside of 72.8% from the stock's current price. View Analyst Price Targets for Myovant Sciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myovant Sciences.

News stories about MYOV stock have been trending neutral recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Myovant Sciences earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Myovant Sciences.

Myovant Sciences saw a drop in short interest in the month of November. As of November 29th, there was short interest totalling 3,140,000 shares, a drop of 28.8% from the November 14th total of 4,410,000 shares. Based on an average daily volume of 2,350,000 shares, the short-interest ratio is currently 1.3 days. Approximately 9.8% of the company's stock are sold short. View Myovant Sciences' Current Options Chain.

Some companies that are related to Myovant Sciences include Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), FibroGen (FGEN), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), Intercept Pharmaceuticals (ICPT), SAGE Therapeutics (SAGE), Blueprint Medicines (BPMC), Taro Pharmaceutical Industries (TARO), Evotec (EVTCY), Alkermes (ALKS), GW Pharmaceuticals PLC- (GWPH) and HUTCHISON CHINA/S (HCM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Amarin (AMRN), Exelixis (EXEL), Fate Therapeutics (FATE), Revance Therapeutics (RVNC), Viking Therapeutics (VKTX), Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), Uniqure (QURE), SCYNEXIS (SCYX) and Energy Transfer LP Unit (ET).

(MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Myovant Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Eventide Asset Management LLC (5.24%), Great Point Partners LLC (0.36%), Point72 Asset Management L.P. (0.23%), LVW Advisors LLC (0.13%), State Street Corp (0.06%) and Millennium Management LLC (0.05%). Company insiders that own Myovant Sciences stock include Andrew Lo, Ferreira Juan Camilo Arjona, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Mark Altmeyer, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Institutional Ownership Trends for Myovant Sciences.

MYOV stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P. and Millennium Management LLC. View Insider Buying and Selling for Myovant Sciences.

MYOV stock was purchased by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Great Point Partners LLC, LVW Advisors LLC, State Street Corp, Virginia Retirement Systems ET AL, Tower Research Capital LLC TRC and Barclays PLC. Company insiders that have bought Myovant Sciences stock in the last two years include Andrew Lo, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Mark Altmeyer, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Insider Buying and Selling for Myovant Sciences.

Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MYOV stock can currently be purchased for approximately $15.05.

Myovant Sciences has a market capitalization of $1.35 billion. The company earns $-273,550,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis. Myovant Sciences employs 86 workers across the globe.View Additional Information About Myovant Sciences.

The official website for Myovant Sciences is http://www.myovant.com/.

Myovant Sciences' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3347 or via email at [email protected]